ABSTRACT
Objectives
This study aims to systematically review the studies on the cost-effectiveness of stereotactic body radiotherapy (SBRT) in the treatment of non–small-cell lung cancer (NSCLC).
Methods
A systematic literature search was performed in databases from 2000 through April 2021. The search terms included ‘economics,’ ‘cost,’ ‘cost effectiveness,’ ‘SBRT,’ and all names for NSCLC. Two reviewers independently screened the titles, abstracts and full texts to determine the studies for the final sample. The quality of the included studies was assessed using the Quality of Health Economic Studies checklist.
Results
Eleven studies were identified and included in our final review. SBRT was reported to be a cost-effective (5 of 5) option compared to conventional radiotherapy, radiofrequency ablation, and best supportive care for medically inoperable, early-stage NSCLC. However, the identified studies revealed that no single treatment was found to be more cost-effective than others between SBRT and surgical interventions. The key drivers of this cost-effectiveness were the cost of the treatment, utility value, and the rate of surgical mortality.
Conclusions
SBRT may be considered a more cost-effective strategy for medically inoperable, early-stage NSCLC. Considering the limited studies available, more related research should be conducted to further validate these results.
Declaration of interest
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contributions
Conception and design: H Wang, C Jin, S Hu. Data acquisition: H Sun, H Wang. Analysis and interpretation of data: H Sun, H Wang. Drafting, revision of the manuscript: H Sun, Y Chen, H Wang. All authors agreed on the final version of the manuscript to be published.